Tag Archives: Alethia Young

TG Therapeutics (TGTX) Receives a Buy from Cantor Fitzgerald

In a report released yesterday, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $17. The company’s shares closed on Friday at $7.56. Young commented: “: We reiterate

Cantor Fitzgerald Reiterates a Buy Rating on Xencor Inc (XNCR)

In a report issued on May 10, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Xencor Inc (XNCR – Research Report), with a price target of $40. The company’s shares closed on Friday at $35.64. Young noted: “.

MyoKardia Inc (MYOK) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young maintained a Buy rating on MyoKardia Inc (MYOK – Research Report) yesterday and set a price target of $90. The company’s shares closed yesterday at $47.95. Young observed: “: 12-month price target of $90. MYOK

Analysts’ Top Healthcare Picks: Arena Pharma (ARNA), Amicus (FOLD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arena Pharma (ARNA – Research Report) and Amicus (FOLD – Research Report) with bullish sentiments. Arena Pharma (ARNA) Cantor Fitzgerald analyst Alethia

Cantor Fitzgerald Thinks Gilead Sciences’ Stock is Going to Recover

In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $87. The company’s shares opened today at $62.47, close to its 52-week low of

Cantor Fitzgerald Keeps Their Buy Rating on Alnylam Pharma (ALNY)

In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $135. The company’s shares closed yesterday at $90.17. Young observed: “: We reiterate our